NASDAQ:SCNX Scienture (SCNX) Stock Price, News & Analysis $0.40 +0.01 (+2.93%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Scienture Stock (NASDAQ:SCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scienture alerts:Sign Up Key Stats Today's Range$0.38▼$0.4150-Day Range$0.33▼$0.4252-Week Range$0.24▼$2.60Volume278,060 shsAverage Volume3.91 million shsMarket Capitalization$16.25 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingHold Company Overview Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. Read More Scienture Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreSCNX MarketRank™: Scienture scored higher than 51% of companies evaluated by MarketBeat, and ranked 470th out of 838 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingScienture has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialScienture has a consensus price target of $1.50, representing about 275.0% upside from its current price of $0.40.Amount of Analyst CoverageScienture has only been the subject of 1 research reports in the past 90 days.Read more about Scienture's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioScienture has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scienture's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.93% of the float of Scienture has been sold short.Short Interest Ratio / Days to CoverScienture has a short interest ratio ("days to cover") of 3.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scienture has recently decreased by 20.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScienture does not currently pay a dividend.Dividend GrowthScienture does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Scienture this week, compared to 2 articles on an average week.Search Interest2 people have searched for SCNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Scienture to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scienture insiders have not sold or bought any company stock.Percentage Held by Insiders21.39% of the stock of Scienture is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.68% of the stock of Scienture is held by institutions.Read more about Scienture's insider trading history. Receive SCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scienture and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNX Stock News HeadlinesScienture (NASDAQ:SCNX) Trading Down 6.6% - Time to Sell?July 22 at 2:20 AM | americanbankingnews.comScienture Holdings stock jumps over 20% pre-market: Here's whyJuly 10, 2026 | msn.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.July 22 at 1:00 AM | Stansberry Research (Ad)SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to WholesalersJuly 9, 2026 | finance.yahoo.comSCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to WholesalersJuly 9, 2026 | globenewswire.comSCNX Share News TodayJuly 4, 2026 | uk.investing.comScienture Holdings (SCNX) Stock Forecast & Price TargetJune 25, 2026 | investing.comScienture Holdings Stock Short Interest Report | NASDAQ:SCNX | BenzingaJune 24, 2026 | benzinga.comSee More Headlines SCNX Stock Analysis - Frequently Asked Questions How have SCNX shares performed this year? Scienture's stock was trading at $0.51 at the beginning of the year. Since then, SCNX stock has decreased by 21.6% and is now trading at $0.40. How were Scienture's earnings last quarter? Scienture Holdings, Inc. (NASDAQ:SCNX) announced its earnings results on Friday, May, 15th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.15. The company earned $0.06 million during the quarter, compared to analyst estimates of $0.40 million. How do I buy shares of Scienture? Shares of SCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scienture own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scienture investors own include Cogent Communications (CCOI), Cavco Industries (CVCO), Liberty Broadband (LBRDK), Liberty Global (LBTYB), PayPal (PYPL), Roku (ROKU) and Arch Capital Group (ACGL). Company Calendar Last Earnings5/15/2026Today7/22/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 SCNX's financial health is in the Yellow zone, according to TradeSmith. SCNX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryWholesale Current SymbolNASDAQ:SCNX Previous SymbolNASDAQ:MEDS CIK1382574 Webwww.trxadehealth.com Phone(800) 261-0281Fax800-265-6932EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Scienture$1.50 High Price Target$1.50 Low Price Target$1.50 Potential Upside/Downside+275.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.51 million Net MarginsN/A Pretax Margin-9,191.82% Return on Equity-56.28% Return on Assets-44.76% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.63 Sales & Book Value Annual Sales$430 thousand Price / Sales37.80 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book0.23Miscellaneous Outstanding Shares40,630,000Free Float31,940,000Market Cap$16.25 million OptionableN/A Beta3.28 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SCNX) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
